|By PR Newswire||
|March 13, 2014 06:30 AM EDT||
CALGARY, March 13, 2014 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the year ended December 31, 2014.
"In 2013, we reported data from a number of clinical studies, which included our first data correlating specific biomarkers with survival in NSCLC lung cancer patients and culminated with the reporting of our first randomized data in head and neck cancer," said Dr. Brad Thompson, President and CEO of Oncolytics. "Our randomized clinical program continues to move ahead with six sponsored studies currently enrolling patients in a range of indications. Each of these studies will advance in parallel with our ongoing head and neck program which we are currently in the process of designing a follow-on registration study for discussion with regulators."
Since January 1, 2013, specific highlights announced by the Company include:
Clinical Trial Results
- Top-line data for the endpoints in a double blinded, randomized clinical study examining REOLYSIN® in combination with carboplatin and paclitaxel in patients with second-line platinum-refractory, taxane-naïve head and neck cancers (REO 018). An analysis was performed on an intent-to-treat basis of 118 patients with loco-regional head and neck cancer, with or without metastases. Patients in the control arm were treated with carboplatin and paclitaxel, while patients in the test arm were treated with carboplatin, paclitaxel and REOLYSIN. The analysis showed a median progression free survival (PFS) of 94 days (13.4 weeks) in the test arm (n=62), versus 50 days (7.1 weeks) in the control arm (n=56). The test arm maintained a PFS benefit over the control arm through five cycles of therapy. An analysis of 88 loco-regional patients that did not receive additional therapy following discontinuation of study treatment showed a median overall survival (OS) of 150 days (21.4 weeks) in the test arm (n=50), versus 115 days (16.4 weeks) in the control arm (n=38). REOLYSIN was deemed safe and well-tolerated by patients. The side effects experienced by patients in the test arm of the study were consistent with expectations based on outcomes of earlier clinical studies using REOLYSIN. Patients on the test arm of the study experienced a higher incidence of flu-like symptoms consistent with treatment with a virus, most commonly mild fever, chills, nausea and diarrhea, on both a per-patient and a per-cycle basis. Fewer patients required dose reductions of paclitaxel due to neuropathy or neurotoxicity on the test arm than the control arm (zero in the test arm versus six in the control arm; p=0.028). On this basis, the Company intends to explore the potential chemoprotective and neuroprotective properties of REOLYSIN in future clinical studies;
- Positive final results from a U.S. Phase 2 study examining the use of REOLYSIN in combination with carboplatin and paclitaxel in patients with stage IV non-small cell lung cancer (NSCLC) with Kras or EGFR-activated tumors (REO 016). Response evaluation for 36 evaluable patients showed 11 partial responses (PR) (30%) (EGFR amplified, five; BRAF two; Kras, three; EGFR mutated, one), 21 stable disease (SD), and four progressive disease (PD). The data also correlated a number of molecular abnormalities with best response, PFS and one-year survival. Current data in these patients demonstrates that 20 of 36 evaluable patients (56%) survived a year or more. There were 13 patients with only EGFR mutations or amplifications, of whom nine (69.2%) survived a year or longer. Four of four (100%) patients with BRAF and EGFR amplification survived a year or longer;
- Final tumor response and PFS data from a U.S. Phase 2 clinical trial in patients with squamous cell carcinoma of the lung (SCCLC) using intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel (REO 021). Of the 25 evaluable patients who had more than one cycle of therapy, 23 (92%) exhibited overall tumor shrinkage. When evaluated for best response, which is the best percentage response recorded on study compared to baseline, 10 patients (40%) had PR, while a further 14 (56%) showed SD, and one (4%), had PD. Using RECIST criteria to evaluate best overall response, 10 patients (40%) had PRs, 12 (48%) showed SD and three (12%), had PD. 31.8% of patients with sufficient follow up had a PFS greater than six months;
- Reaching the stage 1 endpoint in a U.S. Phase 2 clinical trial in patients with metastatic melanoma (REO 020) after only 14 patients were enrolled. The primary objective of this Phase 2 trial was to assess the antitumor effect of the treatment regimen in the study population in terms of objective response rates. The secondary objectives were to assess progression-free survival and overall survival for the treatment regimen; the disease control rate (complete response (CR) plus PR plus SD) and duration, and to assess the safety and tolerability of the treatment regimen in the study population. Three of the 14 patients exhibited a PR, and an additional seven patients had SD for a disease control rate of 71.5%; and
Positive preliminary results from a Phase 1 study examining the
intravenous administration of REOLYSIN in combination with FOLFIRI in
patients with metastatic colorectal cancer (REO 022) in a poster
presentation at the ASCO Gastrointestinal Cancers Symposium. Of the 18
patients evaluable for response there was one PR and nine had SD. The
combined overall PFS of FOLFIRI-naïve and FOLFIRI-failed patients was
7.4 months. The authors concluded that the combination of REOLYSIN and
FOLFIRI was safe and well tolerated and resulted in disease control in
the majority of evaluable patients, including patients that had
previously progressed on Irinotecan.
- At December 31, 2013 the Company reported $27.2 million in cash, cash equivalents and short-term investments; and
- Subsequent to year end, entry into a share purchase agreement with Lincoln Park Capital Fund, LLC that will provide an initial investment in Oncolytics of US$1.0 million and make available additional periodic investments of up to US$25.0 million over a 30-month term.
|ONCOLYTICS BIOTECH INC.|
|CONSOLIDATED STATEMENTS OF FINANCIAL POSITION|
|Cash and cash equivalents||25,220,328||19,323,541|
|Total current assets||27,689,568||21,668,842|
|Property and equipment||532,459||409,248|
|Total non-current assets||532,459||409,248|
|Liabilities And Shareholders' Equity|
|Accounts payable and accrued liabilities||6,008,661||7,291,310|
|Total current liabilities||6,008,661||7,291,310|
|Issued: December 31, 2013 - 84,803,818|
|December 31, 2012 - 76,710,285||228,612,564||198,155,091|
|Accumulated other comprehensive loss||79,698||(57,115)|
|Total shareholders' equity||22,213,366||14,786,780|
|Total liabilities and equity||28,222,027||22,078,090|
|ONCOLYTICS BIOTECH INC.|
|CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS|
|For the years ending December 31,||
|Research and development||18,506,064||31,402,625||23,386,685|
|Loss before the following||(23,898,724)||(36,688,050)||(28,721,267)|
|Write down of asset available for sale||—||—||(735,681)|
|Change in fair value of warrant liability||—||—||36,000|
|Loss before income taxes||(23,527,239)||(36,343,047)||(29,004,701)|
|Income tax expense||(5,408)||(30,474)||(40,000)|
Other comprehensive income items that may
be reclassified to net loss
|Net comprehensive loss||(23,395,834)||(36,313,135)||(29,005,542)|
|Basic and diluted loss per common share||(0.28)||(0.48)||(0.41)|
|Weighted average number of shares (basic and diluted)||83,530,981||76,102,062||70,911,526|
|ONCOLYTICS BIOTECH INC.|
|CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY|
|As at December 31, 2010||155,439,610||4,108,652||19,399,489||(156,660)||(142,396,131)||36,394,960|
|Net loss and comprehensive income||—||—||—||39,159||(29,044,701)||(29,005,542)|
|Exercise of warrants||21,487,080||(1,455,025)||—||—||—||20,032,055|
|Exercise of stock options||355,876||—||(62,473)||—||—||293,403|
|Share based compensation||—||—||1,805,503||—||—||1,805,503|
|As at December 31, 2011||177,282,566||2,653,627||21,142,519||(117,501)||(171,440,832)||29,520,379|
|Net loss and comprehensive income||—||—||—||60,386||(36,373,521)||(36,313,135)|
|Issued, pursuant to a bought deal financing||19,386,903||376,892||—||—||—||19,763,795|
|Expiry of warrants||—||(2,653,627)||2,653,627||—||—||—|
|Exercise of stock options||1,485,622||—||(400,632)||—||—||1,084,990|
|Share based compensation||—||—||730,751||—||—||730,751|
|As at December 31, 2012||198,155,091||376,892||24,126,265||(57,115)||(207,814,353)||14,786,780|
|Net loss and comprehensive income||—||—||—||136,813||(23,532,647)||(23,395,834)|
|Issued, pursuant to a bought deal financing||30,218,796||—||—||—||—||30,218,796|
|Expiry of warrants||—||—||—||—||—||—|
|Exercise of stock options||238,677||—||(59,437)||—||—||179,240|
|Share based compensation||—||—||424,384||—||—||424,384|
|As at December 31, 2013||228,612,564||376,892||24,491,212||79,698||(231,347,000)||22,213,366|
|ONCOLYTICS BIOTECH INC.|
|CONSOLIDATED STATEMENTS OF CASH FLOWS|
|For the years ending December 31,||
|Net loss for the year||(23,532,647)||(36,373,521)||(29,044,701)|
|Amortization - property and equipment||131,623||109,275||92,590|
|Share based compensation||424,384||730,751||1,805,503|
|Change in fair value of warrant liability||—||—||(36,000)|
|Write down of asset available for sale||—||—||735,681|
|Unrealized foreign exchange loss||(89,721)||89,890||115,234|
|Net change in non-cash working capital||(1,374,172)||1,187,967||3,790,510|
|Cash used in operating activities||(24,440,533)||(34,255,638)||(22,541,183)|
|Acquisition of property and equipment||(254,834)||(126,412)||(257,790)|
|Redemption (purchase) of short-term investments||(32,416)||(32,441)||1,672,459|
|Cash provided by (used in) investing activities||(287,250)||(158,853)||1,414,669|
|Proceeds from exercise of stock options and warrants||179,240||1,084,990||14,824,658|
|Proceeds from public offering||30,218,796||19,763,795||—|
|Cash provided by financing activities||30,398,036||20,848,785||14,824,658|
|Increase (decrease) in cash||5,670,253||(13,565,706)||(6,301,856)|
|Cash and cash equivalents, beginning of year||19,323,541||32,918,751||39,296,682|
|Impact of foreign exchange on cash and cash equivalents||226,534||(29,504)||(76,075)|
|Cash and cash equivalents, end of year||25,220,328||19,323,541||32,918,751|
To view the Company's Fiscal 2013 Consolidated Financial Statements, related Notes to Consolidated Financial Statements, and Management's Discussion and Analysis, please see the Company's annual filings which will be available on www.sedar.com and on www.oncolyticsbiotech.com/for-investors/financials.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's belief as to the potential of REOLYSIN as a cancer therapeutic; the Company's expectations as to the success of its research and development programs in 2014 and beyond, the Company's planned operations, the value of the additional patents and intellectual property; the Company's expectations related to the applications of the patented technology; the Company's expectations as to adequacy of its existing capital resources; the design, timing, success of planned clinical trial programs; and other statements related to anticipated developments in the Company's business and technologies involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.
SOURCE Oncolytics Biotech Inc.
In the midst of the widespread popularity and adoption of cloud computing, it seems like everything is being offered “as a Service” these days: Infrastructure? Check. Platform? You bet. Software? Absolutely. Toaster? It’s only a matter of time. With service providers positioning vastly differing offerings under a generic “cloud” umbrella, it’s all too easy to get confused about what’s actually being offered. In his session at 16th Cloud Expo, Kevin Hazard, Director of Digital Content for SoftL...
Jun. 30, 2015 05:00 PM EDT Reads: 2,071
Agile, which started in the development organization, has gradually expanded into other areas downstream - namely IT and Operations. Teams – then teams of teams – have streamlined processes, improved feedback loops and driven a much faster pace into IT departments which have had profound effects on the entire organization. In his session at DevOps Summit, Anders Wallgren, Chief Technology Officer of Electric Cloud, will discuss how DevOps and Continuous Delivery have emerged to help connect dev...
Jun. 30, 2015 04:39 PM EDT Reads: 508
Today air travel is a minefield of delays, hassles and customer disappointment. Airlines struggle to revitalize the experience. GE and M2Mi will demonstrate practical examples of how IoT solutions are helping airlines bring back personalization, reduce trip time and improve reliability. In their session at @ThingsExpo, Shyam Varan Nath, Principal Architect with GE, and Dr. Sarah Cooper, M2Mi’s VP Business Development and Engineering, will explore the IoT cloud-based platform technologies drivi...
Jun. 30, 2015 04:21 PM EDT Reads: 535
Containers are changing the security landscape for software development and deployment. As with any security solutions, security approaches that work for developers, operations personnel and security professionals is a requirement. In his session at DevOps Summit, Kevin Gilpin, CTO and Co-Founder of Conjur, will discuss various security considerations for container-based infrastructure and related DevOps workflows.
Jun. 30, 2015 03:59 PM EDT Reads: 494
It is one thing to build single industrial IoT applications, but what will it take to build the Smart Cities and truly society-changing applications of the future? The technology won’t be the problem, it will be the number of parties that need to work together and be aligned in their motivation to succeed. In his session at @ThingsExpo, Jason Mondanaro, Director, Product Management at Metanga, discussed how you can plan to cooperate, partner, and form lasting all-star teams to change the world...
Jun. 30, 2015 02:15 PM EDT Reads: 2,144
Overgrown applications have given way to modular applications, driven by the need to break larger problems into smaller problems. Similarly large monolithic development processes have been forced to be broken into smaller agile development cycles. Looking at trends in software development, microservices architectures meet the same demands. Additional benefits of microservices architectures are compartmentalization and a limited impact of service failure versus a complete software malfunction. ...
Jun. 30, 2015 01:56 PM EDT Reads: 621
Internet of Things is moving from being a hype to a reality. Experts estimate that internet connected cars will grow to 152 million, while over 100 million internet connected wireless light bulbs and lamps will be operational by 2020. These and many other intriguing statistics highlight the importance of Internet powered devices and how market penetration is going to multiply many times over in the next few years.
Jun. 30, 2015 01:45 PM EDT Reads: 1,986
Internet of Things (IoT) will be a hybrid ecosystem of diverse devices and sensors collaborating with operational and enterprise systems to create the next big application. In their session at @ThingsExpo, Bramh Gupta, founder and CEO of robomq.io, and Fred Yatzeck, principal architect leading product development at robomq.io, discussed how choosing the right middleware and integration strategy from the get-go will enable IoT solution developers to adapt and grow with the industry, while at th...
Jun. 30, 2015 01:45 PM EDT Reads: 1,853
Containers have changed the mind of IT in DevOps. They enable developers to work with dev, test, stage and production environments identically. Containers provide the right abstraction for microservices and many cloud platforms have integrated them into deployment pipelines. DevOps and Containers together help companies to achieve their business goals faster and more effectively. In his session at DevOps Summit, Ruslan Synytsky, CEO and Co-founder of Jelastic, reviewed the current landscape of...
Jun. 30, 2015 01:30 PM EDT Reads: 2,106
Malicious agents are moving faster than the speed of business. Even more worrisome, most companies are relying on legacy approaches to security that are no longer capable of meeting current threats. In the modern cloud, threat diversity is rapidly expanding, necessitating more sophisticated security protocols than those used in the past or in desktop environments. Yet companies are falling for cloud security myths that were truths at one time but have evolved out of existence.
Jun. 30, 2015 01:15 PM EDT Reads: 2,041
The cloud has transformed how we think about software quality. Instead of preventing failures, we must focus on automatic recovery from failure. In other words, resilience trumps traditional quality measures. Continuous delivery models further squeeze traditional notions of quality. Remember the venerable project management Iron Triangle? Among time, scope, and cost, you can only fix two or quality will suffer. Only in today's DevOps world, continuous testing, integration, and deployment upend...
Jun. 30, 2015 12:30 PM EDT Reads: 1,839
The time is ripe for high speed resilient software defined storage solutions with unlimited scalability. ISS has been working with the leading open source projects and developed a commercial high performance solution that is able to grow forever without performance limitations. In his session at Cloud Expo, Alex Gorbachev, President of Intelligent Systems Services Inc., shared foundation principles of Ceph architecture, as well as the design to deliver this storage to traditional SAN storage co...
Jun. 30, 2015 10:30 AM EDT Reads: 1,884
To many people, IoT is a buzzword whose value is not understood. Many people think IoT is all about wearables and home automation. In his session at @ThingsExpo, Mike Kavis, Vice President & Principal Cloud Architect at Cloud Technology Partners, discussed some incredible game-changing use cases and how they are transforming industries like agriculture, manufacturing, health care, and smart cities. He will discuss cool technologies like smart dust, robotics, smart labels, and much more. Prepare...
Jun. 30, 2015 10:20 AM EDT Reads: 539
"We provide a web application framework for building really sophisticated web applications that run on a browser without any installation need so we get used for biotech, defense, and banking applications," noted Charles Kendrick, CTO and Chief Architect at Isomorphic Software, in this SYS-CON.tv interview at @DevOpsSummit (http://DevOpsSummit.SYS-CON.com), held June 9-11, 2015, at the Javits Center in New York
Jun. 30, 2015 10:15 AM EDT Reads: 836
The Internet of Things is not only adding billions of sensors and billions of terabytes to the Internet. It is also forcing a fundamental change in the way we envision Information Technology. For the first time, more data is being created by devices at the edge of the Internet rather than from centralized systems. What does this mean for today's IT professional? In this Power Panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists addressed this very serious issue of pro...
Jun. 30, 2015 09:45 AM EDT Reads: 884